O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Séverine Vermeire(KU Leuven), Brian G. Feagan(Western University), Yinghua Lang, Stephan R. Targan(Cedars-Sinai Medical Center), Marion Blank(Janssen (United States)), Edward V. Loftus(Mayo Clinic), Wim de Villiers(University of Cape Town), Pierre Desreumaux(Active Biotech (Sweden)), Long-Long Gao(Janssen (United States)), Subrata Ghosh(University College Cork), Scott Lee(University of Washington), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Christopher Gasink(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Stephen B. Hanauer(Northwestern University)
Cited by 48
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k